Cardiac Toxicity in Lung Cancer Patients undergoing Radiotherapy
Research type
Research Study
Full title
A prospective study investigating how to avoid cardiac toxicity in lung cancer patients treated with curative-intent radiotherapy to improve survival, funded by Yorkshire Cancer Research.
IRAS ID
230736
Contact name
Corinne Faivre-Finn
Contact email
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 3 months, 1 days
Research summary
Radiotherapy plays a major role in the treatment of lung cancer and recent advances in radiotherapy have led to better cure rates. However, the radiotherapy dose needed to destroy the cancer cells can unfortunately also damage the surrounding organs, including the heart. The precise way the damage is caused and which areas of the heart are more sensitive to radiation is not currently known. Earlier work related to this project has analysed large amounts of existing radiotherapy treatment data to help understand this. We hope that by working out the exact dose of radiotherapy which can be safely given to the heart, this will lead to radiotherapy which can avoid the sensitive areas of the heart where possible in lung cancer patients. We estimate that this should lead to an approximately 10% improvement in survival of lung cancer patients at 1 year.
In this study we will:
• Collect blood samples and take scans of the heart in a group of patients from 2 hospitals (in Manchester and Leeds).
• Match the results of the blood tests and scans with information relating the patient's outcomes (e.g. side effects and survival).REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
18/NW/0706
Date of REC Opinion
25 Oct 2018
REC opinion
Favourable Opinion